Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 484-487

  Mowla, Arash ^a,b   Mosavinasab, Masoud ^a   Haghshenas, Hasan ^a   Haghighi, Afshin Borhani ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; RIVASTIGMINE; SEROTONIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD CHANGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 34548699679     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31814b98c1     Document Type: Article

References (31)

1. Meltze CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407-430.
2. Wenk GL, Pierce DJ, Struble RG, et al. Age related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging. 1989;10:11-19.
3. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm. 1993;91:135-159.
4. Rossor M, Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull. 1986;42:70-74.
5. Decker MW, McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse. 1991;7:151-168.
6. Riekkinen M, Tolonen R, Riekkinen P Jr . Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. Brain Res. 1994;649:174-180.
7. Lai MK, Tsang SW, Francis PT, et al. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport. 2002;13:1175-1178.
8. Newhouse P, Tatro A, Naylor M, et al. Alzheimer's disease, serotonin system and tryptophan depletion. Am J Geriatr Psychiatry. 2002;10:483-484.
9. Hayward G, Goodwin GM, Cowen JP, et al. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry. 2005;57:517-524.
10. Abe Y, Aoyagi A, Hara T, et al. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J Pharmacol Sci. 2003;93:95-105.
11. Erkinjuntti T, Lee DH, Gao F, et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease. Arch Neurol. 1993;50:305-310.
12. Gould E, McEwen BS, Tanapat P, et al. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci. 1997;17:2492-2498.
13. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5:262-269.
14. Manev R, Uz T, Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur J Pharmacol. 2001;1:420.
15. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
16. Vermetten E, Vythilingam M, Southwick S, et al. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry. 2003;54:693-702.
17. Vythilingam M, Vermetten E, Anderson GM, et al. Hippocampus volume, memory, and cortical status in major depressive disorder: effects of treatment. Biol Psychiatry. 2004;56:101-111.
18. Schmitt JA, Wingen M, Ramaekers JG, et al. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12:2473-2486.
19. Reisberg B, Ferris SH. Brief Cognitive Rating Scale (BCRS). Psychopharmacol Bull. 1988;24:629-636.
20. Hachinski VC, Iliff LD, Zhiak E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
21. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res. 1975;12:189-198.
23. Wechsler D. The Wechsler Memory Scale. 3rd ed. Psychological Corp (Harcourt): San Antonio, TX; 1997.
24. Iverson GL. Interpreting change on the WAIS-III/WMS-III in clinical samples. Arch Clin Neuropsychol. 2001;16:183-191.
25. Ourangee M, Atef-Vahid MK, Ashayeri H. Normalization of Wechsler Memory Scale-Revised in Shiraz. Andisheh Va Raftar. 2002;4:56-66. [In Persian].
26. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
27. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Heath Service, Alcohol, Drug Abuse, and Mental Retardation Branch, Division of Extramural Research Programs; 1976: 218-222.
28. Balesteri L, Grossberg A, Grossberg GT. Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. Int Psychogeriatr. 2002;12:59-62.
29. Patterson MB, Mack JL, Neundorfer MM, et al. Assessment of functional ability in Alzheimer's disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living. Alzheimer Dis Assoc Disord. 1992;6:145-163.
30. Proctor AW, Francis PT, Stratmann GC, et al. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochem Res. 1992;17:917-922.
31. Morretti R, Torre P, Antonella RM, et al. Depression and Alzheimer's disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 2002;17:338-344.